Lunsekimig
Sponsors
Sanofi-Aventis Recherche & Developpement, Sanofi
Conditions
AsthmaChronic Obstructive Pulmonary DiseaseChronic Rhinosinusitis With Nasal PolypsDermatitis AtopicRespiratory tract diseases
Phase 2
Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma
CompletedNCT06102005
Start: 2023-10-16End: 2026-03-11Updated: 2026-03-17
A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps
CompletedNCT06454240
Start: 2024-07-17End: 2026-04-23Updated: 2026-04-28
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma
Enrolling by invitationNCT06609239
Start: 2024-09-30End: 2031-01-20Target: 900Updated: 2026-06-22
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
Active, not recruitingNCT06676319
Start: 2024-11-07End: 2027-07-19Updated: 2026-07-01
A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis
CompletedNCT06790121
Start: 2025-01-30End: 2026-04-09Updated: 2026-04-21
Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study
Enrolling by invitationNCT06914908
Start: 2025-05-12End: 2031-01-29Target: 71Updated: 2026-07-02
A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype
Not yet recruitingCTIS2024-518016-39-00
Target: 193Updated: 2026-07-07
A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype
Not yet recruitingCTIS2024-518213-25-00
Target: 248Updated: 2026-07-07
Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
RecruitingNCT07190209
Start: 2025-09-16End: 2030-01-22Target: 942Updated: 2026-06-15
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
RecruitingNCT07190222
Start: 2025-09-17End: 2030-01-22Target: 942Updated: 2026-06-15